Frederick J. Raal

Nov 18, 2024 | radcliffecardiology.com | Harriette Van Spall |Tor Biering-Sørensen |Dean Kereiakes |Frederick J. Raal

AHA Conference 2024 — New insights from the NUDGE-FLU Program on electronic nudges to increase influenza vaccination amongst patients with a history of myocardial infarction. Dr Harriette Van Spall (McMaster University, CA) sits down with the principal investigator of the NUDGE-FLU trial, (NCT05542004) Dr Tor Biering-Sørensen, to discuss the latest insights and data.

Sep 8, 2023 | healio.com | Scott Buzby |Richard Smith |Frederick J. Raal

Source/Disclosures Source: Raal FJ, et al. Late-breaking science on pharmacology. Presented at: European Society of Cardiology Congress; Aug. 25-28, 2023; Amsterdam (hybrid meeting). Disclosures: Raal reports receiving research grants from Amgen, Arrowhead, LIB Therapeutics, Novartis, Regeneron and Sanofi and receiving honoraria, consultant fees and/or speaking fees from Amgen, LIB Therapeutics, Novartis, Regeneron and Sanofi. You've successfully added Cardiology: CHD/Prevention to your alerts.

Aug 29, 2023 | icrjournal.com | Gilles Montalescot |Frederick J. Raal

ESC 23 — Dr Yan Yan (Beijing Anzhen Hospital, CN) and Prof Gilles Montalescot (Pitie Salpetriere APHP University Hospital, FR) discusses the findings from a comparison of anticoagulation prolongation vs no anticoagulation in STEMI patients post-primary PCI (RIGHT) (NCT03664180).

Aug 28, 2023 | ecrjournal.com | Frederick J. Raal |Ilan Goldenberg

ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104). The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in patients with heterozygous familial hypercholesterolemia as compared to placebo.